Dawn Halkuff Biography and Net Worth

Director of Xeris Biopharma

Dawn Halkuﬀ was most recently the Chief Executive Oﬃcer of Ideal Protein, a wellness company focused on medically developed weight loss protocols.

Ms. Halkuﬀ has held numerous senior-level commercial and marketing positions over 20 years, most recently as Chief Commercial Officer at TherapeuticsMD, Prior TherapeuticsMD, she was Senior Vice President of the Pﬁzer Consumer Healthcare Wellness Organization and a member of the Consumer Global Leadership Team. Ms. Halkuﬀ was also commercial lead for sales and marketing of the Pﬁzer Women’s Health Division, focusing on the company’s reinvestment in hormone therapy treatment, including Premarin® Vaginal Cream and oral hot ﬂash treatments. From 2005–2010, Ms. Halkuﬀ was Head of Global Innovation at Weight Watchers International, where she created new weight-loss products, services, and solutions for women worldwide.

She holds a BA in Psychology from the University of Connecticut and an MBA from Pennsylvania State University.

What is Dawn Halkuff's net worth?: The estimated net worth of Dawn Halkuff is at least $803.85 thousand as of August 12th, 2025. Halkuff owns 115,000 shares of Xeris Biopharma stock worth more than $803,850 as of December 8th. This net worth approximation does not reflect any other investments that Halkuff may own. Learn More about Dawn Halkuff's net worth.
How do I contact Dawn Halkuff?: The corporate mailing address for Halkuff and other Xeris Biopharma executives is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. Xeris Biopharma can also be reached via phone at (844) 445-5704 and via email at [email protected]. Learn More on Dawn Halkuff's contact information.
Has Dawn Halkuff been buying or selling shares of Xeris Biopharma?: Dawn Halkuff has not been actively trading shares of Xeris Biopharma during the past quarter. Most recently, Dawn Halkuff sold 42,500 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a transaction totalling $309,400.00. Following the completion of the sale, the director now directly owns 115,000 shares of the company's stock, valued at $837,200. Learn More on Dawn Halkuff's trading history.
Who are Xeris Biopharma's active insiders?: Xeris Biopharma's insider roster includes Paul Edick (Insider), Dawn Halkuff (Director), Beth Hecht (Insider), John Johnson (Director), Kevin McCulloch (President and Chief Operating Officer), Marla Persky (Director), John Shannon, Jr. (Insider), and Jeffrey Sherman (Director). Learn More on Xeris Biopharma's active insiders.
Are insiders buying or selling shares of Xeris Biopharma?: In the last year, Xeris Biopharma insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $109,500.00. In the last year, insiders at the sold shares 8 times. They sold a total of 304,308 shares worth more than $2,181,194.23. The most recent insider tranaction occured on December, 1st when insider Beth Hecht sold 16,667 shares worth more than $116,835.67. Insiders at Xeris Biopharma own 4.6% of the company. Learn More about insider trades at Xeris Biopharma.
Information on this page was last updated on 12/1/2025.

Dawn Halkuff Insider Trading History at Xeris Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/12/2025	Sell	42,500	$7.28	$309,400.00	115,000

Dawn Halkuff Buying and Selling Activity at Xeris Biopharma

Xeris Biopharma Company Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Today's Range

Now: $6.99

$6.57

$7.06

50 Day Range

MA: $8.10

$6.47

$9.90

2 Week Range

Now: $6.99

$3.14

$10.08

Volume

2,653,141 shs

Average Volume

2,493,037 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58